EP Patent

EP1954241A1 — Sustained-release formulation of zonisamide

Assigned to Orexigen Therapeutics Inc · Expires 2008-08-13 · 18y expired

What this patent protects

Pharmaceutical formulations comprise sustained-release zonisamide. Methods of preparing such pharmaceutical formulations involve intermixing zonisamide with a suitable excipient configured to control the dissolution profile of the zonisamide. Methods of treatment involve administ…

USPTO Abstract

Pharmaceutical formulations comprise sustained-release zonisamide. Methods of preparing such pharmaceutical formulations involve intermixing zonisamide with a suitable excipient configured to control the dissolution profile of the zonisamide. Methods of treatment involve administering the pharmaceutical formulations to patients in need of such treatment.

Drugs covered by this patent

Patent Metadata

Patent number: EP1954241A1
Jurisdiction: EP
Classification: —
Expires: 2008-08-13
Drug substance claim: No
Drug product claim: No
Assignee: Orexigen Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.